VRPX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 3.70%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Virpax Pharmaceuticals Insider Trading History Chart

Virpax Pharmaceuticals Share Price & Price History

^$0.33

▲ +0.0136 (4.30%)

As of 12/20/2024 06:51 PM ET

Days: 30 | 90 | 365

Rare "crisis signal" triggers for third time in U.S. market

From Stansberry Research | Ad

A rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the market crashed 78% (the dot-com bust) and 89% (the Great Depression). Today, according to one of America's leading experts (who has predicted nearly every financial crisis of the last 25 years), what's coming next could soon crash the market by 50% or more, and keep it down for 10, 20, or even 30 years.

Click here for all the details.

Virpax Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/24/2022	Jerrold Sendrow	Director	Buy	450	$12.90	$5,805.00	900
5/18/2022	Anthony P. Mack	CEO	Buy	7,575	$13.40	$101,505.00	25,256
5/18/2022	Eric Floyd	Director	Buy	447	$13.60	$6,079.20	801

This is the worst sign for the U.S. stock market in 50 years

From Stansberry Research | Ad

The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"

Click here to see Dan's new, urgent warning about the U.S. market for 2025.

SEC Filings (Institutional Ownership Changes) for Virpax Pharmaceuticals (NASDAQ:VRPX)

32.23% of Virpax Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Virpax Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
12/10/2024	Garden State Investment Advisory Services LLC	57,300	$40K	0.0%	N/A	1.172%
11/15/2024	Garden State Investment Advisory Services LLC	57,300	$40K	0.0%	N/A	1.172%
11/15/2023	Sabby Management LLC	292,790	$0.23M	0.2%	-26.8%	2.500%
5/13/2022	Warberg Asset Management LLC	17,710	$39K	0.0%	N/A	0.151%
11/17/2021	Altium Capital Management LP	271,846	$1.31M	0.3%	N/A	2.320%
11/16/2021	National Asset Management Inc.	18,600	$90K	0.0%	N/A	0.159%
11/2/2021	Cambridge Investment Research Advisors Inc.	19,420	$93K	0.0%	N/A	0.166%
9/17/2021	Virtu Financial LLC	23,625	$0.11M	0.0%	N/A	0.468%
8/16/2021	Sabby Management LLC	154,737	$0.70M	0.1%	-22.6%	3.120%
8/12/2021	Saltoro Capital LP	17,615	$80K	0.0%	-34.8%	0.355%
5/14/2021	HN Saltoro Capital LP	27,000	$0.13M	0.0%	N/A	0.546%

Data available starting January 2016

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Today's Range

Now: $0.33

$0.32

$0.37

50 Day Range

MA: $0.54

$0.30

$0.76

52 Week Range

Now: $0.33

$0.29

$5.48

Volume

970,033 shs

Average Volume

2,474,614 shs

Market Capitalization

$1.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

Who are the major institutional investors of Virpax Pharmaceuticals?: Virpax Pharmaceuticals' top institutional investors include:
Garden State Investment Advisory Services LLC — 1.17%
Garden State Investment Advisory Services LLC — 1.17%
Learn More about top institutional investors of Virpax Pharmaceuticals stock.
Which institutional investors are buying Virpax Pharmaceuticals stock?: Within the previous quarter, VRPX stock was purchased by institutional investors including:
Garden State Investment Advisory Services LLC
Garden State Investment Advisory Services LLC